476 related articles for article (PubMed ID: 8276565)
1. Methotrexate, vinblastine, adriamycin and cisplatin (MVAC) chemotherapy for the treatment of advanced bladder carcinoma.
Balbay MD; Ozen H; Uluçay S; Sahin A; Ergen A; Koçal C; Remzi D
Int Urol Nephrol; 1993; 25(4):351-7. PubMed ID: 8276565
[TBL] [Abstract][Full Text] [Related]
2. [Neoadjuvant chemotherapy with MVC (methotrexate, vinblastine, cisplatin)in the treatment of infiltrating transitional carcinoma of the bladder].
Campo B; Torelli T; Leidi GL; Corrada P; Bacchioni AM; Ordesi G; Zanitzer L
Arch Ital Urol Nefrol Androl; 1990 Jun; 62(2):237-42. PubMed ID: 2142807
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy for advanced urothelial tract tumors: the M-VAC regimen.
Sternberg CN; Yagoda A; Scher HI
Prog Clin Biol Res; 1988; 277():45-51. PubMed ID: 3054909
[No Abstract] [Full Text] [Related]
4. [Clinical and pathological evaluations of methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) chemotherapy for advanced urothelial cancers].
Takenaka A; Gotoh A; Hara I; Gohji K; Ogawa T; Arakawa S; Matsumoto O; Kamidono S; Hamami G; Itani A
Gan To Kagaku Ryoho; 1990 Sep; 17(9):1909-15. PubMed ID: 2393308
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy.
George L; Bladou F; Bardou VJ; Gravis G; Tallet A; Alzieu C; Serment G; Salem N
Urology; 2004 Sep; 64(3):488-93. PubMed ID: 15351577
[TBL] [Abstract][Full Text] [Related]
6. [Polychemotherapy in advanced bladder cancer. Practicality and clinical results].
Klän R; Knispel H; Huland H
Urologe A; 1992 Jul; 31(4):247-50. PubMed ID: 1514213
[TBL] [Abstract][Full Text] [Related]
7. Impact of recombinant human granulocyte colony stimulating factor on dose intensity and toxicity of three cycles of methotrexate, vinblastine, doxorubicin and cisplatin in patients with previously untreated urothelial bladder carcinoma.
Viens P; Gravis G; Bladou F; Lechevallier E; Baume D; Camerlo J; Cowen D; Coulange C; Serment G; Resbeut M; Maraninchi D
Eur Cytokine Netw; 1996 Sep; 7(3):395-9. PubMed ID: 8954183
[TBL] [Abstract][Full Text] [Related]
8. [Conservative treatment of infiltrating cancer of the bladder: neoadjuvant chemotherapy and radiotherapy].
Prié L; Gaston R; Ferrière JM; Richaud P; Bui BN; Guillou ML
Cancer Radiother; 1998 Apr; 2 Suppl 1():62s-66s. PubMed ID: 9749081
[TBL] [Abstract][Full Text] [Related]
9. Impact of methotrexate, vinblastine, adriamycin, and cisplatin chemotherapy in patients with lymph node metastases from transitional cell carcinoma of the lower urinary tract.
Koch MO; Coussens D
Semin Urol; 1993 Feb; 11(1):14-9. PubMed ID: 8465122
[No Abstract] [Full Text] [Related]
10. [Experience with combination chemotherapy consisting of methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) in advanced urothelial cancer].
Nishio Y; Shirahase T; Shichiri Y; Habuchi T; Matsuda T; Nishimura K; Hida S; Okada Y; Yoshida O
Hinyokika Kiyo; 1988 Aug; 34(8):1371-5. PubMed ID: 3195405
[TBL] [Abstract][Full Text] [Related]
11. [The role of M-VAC polychemotherapy in the treatment of advanced urothelial carcinoma of the bladder].
Stöckle M; Meyenburg W; Wellek S; Voges G; Gertenbach U; Thüroff JW; Huber C; Hohenfellner R
Ann Urol (Paris); 1993; 27(1):51-7. PubMed ID: 7682388
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of chemotherapy with magnetic resonance imaging in patients with regionally metastatic or unresectable bladder cancer.
Schrier BP; Peters M; Barentsz JO; Witjes JA
Eur Urol; 2006 Apr; 49(4):698-703. PubMed ID: 16464531
[TBL] [Abstract][Full Text] [Related]
13. [Combination chemotherapy of methotrexate, etoposide, adriamycin and cisplatin (M-EAP) for advanced urothelial cancer].
Hashimura T; Okumura K; Akao T; Nakagawa T
Hinyokika Kiyo; 1991 Jul; 37(7):685-8. PubMed ID: 1927767
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant chemotherapy for deep muscle-invasive transitional cell bladder carcinoma - a practice guideline.
Segal R; Winquist E; Lukka H; Chin JL; Brundage M; Markman BR;
Can J Urol; 2002 Oct; 9(5):1625-33. PubMed ID: 12431323
[TBL] [Abstract][Full Text] [Related]
15. Combination chemotherapy of cisplatin, methotrexate, vinblastine, and high-dose tamoxifen for transitional cell carcinoma.
Hsu CH; Chen J; Wu CY; Cheng AL; Pu YS
Anticancer Res; 2001; 21(1B):711-5. PubMed ID: 11299831
[TBL] [Abstract][Full Text] [Related]
16. Extended experience of neo-adjuvant M-VAC chemotherapy for T1-4 N0 M0 transitional cell carcinoma of the urinary bladder.
Keating JP; Zincke H; Hahn RG; Morgan WR
Prog Clin Biol Res; 1990; 353():119-27. PubMed ID: 2217409
[No Abstract] [Full Text] [Related]
17. [Combination chemotherapy with M-VAC protocol in metastatic urothelial cancer].
Sella A; Flex D; Gafni D; Rabinovitz O; Sulkes A; Baniel J
Harefuah; 1999 Feb; 136(4):268-71, 340, 339. PubMed ID: 10914214
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant methotrexate, vinblastine and cisplatin chemotherapy for invasive transitional cell carcinoma: Taiwan experience.
Wei CH; Hsieh RK; Chiou TJ; Chen KK; Chang LS; Chen PM
J Urol; 1996 Jan; 155(1):118-21. PubMed ID: 7490806
[TBL] [Abstract][Full Text] [Related]
19. Primary cisplatin, methotrexate and vinblastine aiming at bladder preservation in invasive bladder cancer: multivariate analysis on prognostic factors.
Angulo JC; Sanchez-Chapado M; Lopez JI; Flores N
J Urol; 1996 Jun; 155(6):1897-902. PubMed ID: 8618282
[TBL] [Abstract][Full Text] [Related]
20. [Prognosis in pT3b infiltrating tumors of the bladder treated by adjuvant chemotherapy].
Sahwi A; Robert M; Delbos O; Legouffe E; Guiter J; Navratil H
Prog Urol; 1998 Dec; 8(6):1007-11. PubMed ID: 9894259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
